The global arthrogryposis management market is expected to garner a market value of USD 250 Million in 2023 and is expected to accumulate a market value of USD 447.41 Million by registering a CAGR of 6% in the forecast period 2023 to 2033. The market for Arthrogryposis Management registered a CAGR of 4% in the historical period 2018 to 2022.
Studies state that more than 300 genetic disorders (such as spinal muscular atrophy type I and trisomy 18) have been associated with arthrogryposis multiplex congenital. Arthrogryposis Management is required when symptoms such as frozen joints, weakened muscles, and nerve impairment are detected. If abnormalities in the limbs are observed, the doctors may perform diagnostic imaging or ultrasounds of other parts of the fetus's body or genetic testing on the fetus using chorionic villus sampling or amniocentesis.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 250 Million |
| Anticipated Forecast Value (2033) | USD 447.41 Million |
| Projected Growth Rate (2023 to 2033) | 6% CAGR |
According to market research and competitive intelligence provider Future Market Insights- the market for arthrogryposis management reflected a value of 4% during the historical period, 2018 to 2022. Urban lifestyles and degrading habits are expected to increase the demand for Arthrogryposis Management and treatment facilities. Due to the hectic life patterns of the citizens working in cities, there has been an observed increase in stress and sleeplessness. These challenges are emerging as the main factor for the deteriorating health of the urban population.
Arthrogryposis is a rare disorder that occurs in 1 out of every 3000 live births. The number of males and females affected by AMC is approximately equal. The condition has been reported in individuals of Asian, African, and European descent. Isolated congenital contractures affect about 1 in 500 individuals in the general population.
The rise of emerging markets in developing countries is an opportunity that is projected to bolster market growth. In the years to come, increasing focus by government organizations and private agencies like WHO and pharmaceutical companies to create awareness of Arthrogryposis is fuelling the market growth. Thus, the market for Arthrogryposis Management is expected to register a CAGR of 6% in the forecast period 2023 to 2033.
Increased Incidence of Arthrogryposis Cases to Push the Market Growth
In recent years, factors such as increased incidence of arthrogryposis cases, rise in geriatric population, increasing number of government initiatives, ease of purchase, investment by research and development in pharmaceutical companies, increased demand for early diagnosis for arthrogryposis treatment are predicted to drive the market growth.
The expanding senior population, as well as the increased prevalence of osteoarthritis and occurrences of orthopedic injury, are driving market development. In the forthcoming years, the frequency of bone injuries, diabetes, and obesity is expected to climb, bolstering the market.
One of the most common orthopedic operations is total knee arthroplasty (TKA), often known as total knee replacement. In addition, multiple studies have shown that after knee arthroplasty, the obese population's functionality improves.
The investments in healthcare infrastructure have given the market leaders in the market an opportunity to create their mark and stand out and take over the majority of revenue share. According to the Centers for Disease Control and Prevention, an estimated 34.6 million adults will have arthritis-related activity limitations by 2040. This has resulted in a growing preference for active and healthy lifestyles, creating a demand for faster injury-healing processes.
Expensive Cost of Treatment to restrict Market Growth
The expensive treatment of Arthrogryposis Management, less awareness of Arthrogryposis Management disease, and insubstantial treatment options are hampering the market growth.
Furthermore, lack of health remuneration policies, rise in cost, and side effects associated with the use of antibiotics are expected to hinder the market growth.
Improvement in healthcare spending propelling the growth of Arthrogryposis Management in Asia Pacific
The Asia Pacific is expected to exhibit the significant growth rate of all regions over the forecast period, at a CAGR of 5% during the forecast period. The growth is owed to increased awareness, significant increases in healthcare spending, and a rising frequency of arthrogryposis management in the region.
Asia Pacific is an emerging market due to the increase in point of care approach to health & care. An increasing number of hospitals in India and China makes a promising market for the treatment market worldwide.
Technological Advancements Shaping Landscape for Arthrogryposis Management in North America
North America is anticipated to acquire a market share of about 25% in the forecast period. This growth is attributable to the rising prevalence of the condition in the region.
An increasing number of surgeries and the presence of leading technological advancements in the healthcare sector along with the rising medical tourism, high patient awareness levels, an increasing number of accidents, and the growing popularity of minimally invasive surgeries are also widening prospects across the continent.
Furthermore, due to the presence of leading technological advancements in the healthcare sector and healthcare facilities with the advancements in technology, efficient treatments are being introduced.
Surgery as an Effective Treatment to drive the market
According to a study, in some cases, surgery may be necessary to achieve better positioning and increase the range of motion in certain joints, especially the ankles, knees, hips, elbows, or wrists. In rare cases, tendon transfers have been performed to improve muscle function.
Furthermore, according to FMI’s analysis, in order to achieve desirable and long-term results a multidisciplinary approach is required. This includes pediatricians, neurologists, orthopedists, rehabilitation physicians and therapists, and medical geneticists. Genetic counseling may be recommended for affected individuals and their families. Other treatments are symptomatic and supportive.
Hospital Pharmacies to take the lead and drive market growth
The distribution segment has been divided into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. According to the FMI analysis, Hospital pharmacies account for the largest market share.
The requirement for several hospital stays and visits during the Arthrogryposis Management Market facilitates the growth of this segment. Hospitals are also emphasizing the delivery of various comprehensive programs with personalized and professional support in the management of target diseases.
Key players in the Arthrogryposis Management Market are Biochem Pharma, Zydus Cadila, GSK, Vernalis (R&D) Limited, Sanofi, Pfizer Inc, Galderma Laboratories, Mylan N.V., Johnson & Johnson Services, Inc, Medimetriks Pharmaceuticals, Inc, F-Hoffmann-La Roche, Illumina Inc, Thermo Fischer Scientific Inc, Takara Bio Inc, CENTOGENE N.V., Abbott among other domestic and global players.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 250 Million |
| Market Value in 2033 | USD 447.41 Million |
| Growth Rate | CAGR of 6% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Treatment Type, Distribution Channel, Region |
| Regions Covered | North America; Latin America; Europe; Asia Pacific; Middle East & Africa (MEA) |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Germany, UK, France, Spain, Italy, China, Japan, South Korea, Thailand, Indonesia, Singapore, Australia, New Zealand, GCC Countries, South Africa, Israel |
| Key Companies Profiled | Biochem Pharmaceutical Industries Limited; Zydus Cadila; GSK Plc.; Vernalis Plc.; Sanofi S.A.; Pfizer Inc.; Galderma Laboratories L.P.; Viatris Inc.; Johnson & Johnson Services Inc.; Medimetriks Pharmaceuticals Inc.; F. Hoffmann-La Roche Ltd.; Illumina Inc.; Thermo Fischer Scientific Inc.; Takara Bio Inc.; Abbott Laboratories |
| Customization | Available Upon Request |
Table 1: Global Value (US$ Mn) Forecast by Region, 2018 to 2033
Table 2: Global Value (US$ Mn) Forecast by Treatment Type, 2018 to 2033
Table 3: Global Value (US$ Mn) Forecast by Distribution Channel, 2018 to 2033
Table 4: North America Value (US$ Mn) Forecast by Country, 2018 to 2033
Table 5: North America Value (US$ Mn) Forecast by Treatment Type, 2018 to 2033
Table 6: North America Value (US$ Mn) Forecast by Distribution Channel, 2018 to 2033
Table 7: Latin America Value (US$ Mn) Forecast by Country, 2018 to 2033
Table 8: Latin America Value (US$ Mn) Forecast by Treatment Type, 2018 to 2033
Table 9: Latin America Value (US$ Mn) Forecast by Distribution Channel, 2018 to 2033
Table 10: Europe Value (US$ Mn) Forecast by Country, 2018 to 2033
Table 11: Europe Value (US$ Mn) Forecast by Treatment Type, 2018 to 2033
Table 12: Europe Value (US$ Mn) Forecast by Distribution Channel, 2018 to 2033
Table 13: Asia Pacific Value (US$ Mn) Forecast by Country, 2018 to 2033
Table 14: Asia Pacific Value (US$ Mn) Forecast by Treatment Type, 2018 to 2033
Table 15: Asia Pacific Value (US$ Mn) Forecast by Distribution Channel, 2018 to 2033
Table 16: MEA Value (US$ Mn) Forecast by Country, 2018 to 2033
Table 17: MEA Value (US$ Mn) Forecast by Treatment Type, 2018 to 2033
Table 18: MEA Value (US$ Mn) Forecast by Distribution Channel, 2018 to 2033
Figure 1: Global Value (US$ Mn) by Treatment Type, 2023 to 2033
Figure 2: Global Value (US$ Mn) by Distribution Channel, 2023 to 2033
Figure 3: Global Value (US$ Mn) by Region, 2023 to 2033
Figure 4: Global Value (US$ Mn) Analysis by Region, 2018 to 2033
Figure 5: Global Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 6: Global Y to o to Y Growth (%) Projections by Region, 2023 to 2033
Figure 7: Global Value (US$ Mn) Analysis by Treatment Type, 2018 to 2033
Figure 8: Global Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033
Figure 9: Global Y to o to Y Growth (%) Projections by Treatment Type, 2023 to 2033
Figure 10: Global Value (US$ Mn) Analysis by Distribution Channel, 2018 to 2033
Figure 11: Global Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 12: Global Y to o to Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 13: Global Attractiveness by Treatment Type, 2023 to 2033
Figure 14: Global Attractiveness by Distribution Channel, 2023 to 2033
Figure 15: Global Attractiveness by Region, 2023 to 2033
Figure 16: North America Value (US$ Mn) by Treatment Type, 2023 to 2033
Figure 17: North America Value (US$ Mn) by Distribution Channel, 2023 to 2033
Figure 18: North America Value (US$ Mn) by Country, 2023 to 2033
Figure 19: North America Value (US$ Mn) Analysis by Country, 2018 to 2033
Figure 20: North America Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 21: North America Y o to Y Growth (%) Projections by Country, 2023 to 2033
Figure 22: North America Value (US$ Mn) Analysis by Treatment Type, 2018 to 2033
Figure 23: North America Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033
Figure 24: North America Y o to Y Growth (%) Projections by Treatment Type, 2023 to 2033
Figure 25: North America Value (US$ Mn) Analysis by Distribution Channel, 2018 to 2033
Figure 26: North America Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 27: North America Y o to Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 28: North America Attractiveness by Treatment Type, 2023 to 2033
Figure 29: North America Attractiveness by Distribution Channel, 2023 to 2033
Figure 30: North America Attractiveness by Country, 2023 to 2033
Figure 31: Latin America Value (US$ Mn) by Treatment Type, 2023 to 2033
Figure 32: Latin America Value (US$ Mn) by Distribution Channel, 2023 to 2033
Figure 33: Latin America Value (US$ Mn) by Country, 2023 to 2033
Figure 34: Latin America Value (US$ Mn) Analysis by Country, 2018 to 2033
Figure 35: Latin America Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 36: Latin America Y to o to Y Growth (%) Projections by Country, 2023 to 2033
Figure 37: Latin America Value (US$ Mn) Analysis by Treatment Type, 2018 to 2033
Figure 38: Latin America Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033
Figure 39: Latin America Y o to Y Growth (%) Projections by Treatment Type, 2023 to 2033
Figure 40: Latin America Value (US$ Mn) Analysis by Distribution Channel, 2018 to 2033
Figure 41: Latin America Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 42: Latin America Y o to Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 43: Latin America Attractiveness by Treatment Type, 2023 to 2033
Figure 44: Latin America Attractiveness by Distribution Channel, 2023 to 2033
Figure 45: Latin America Attractiveness by Country, 2023 to 2033
Figure 46: Europe Value (US$ Mn) by Treatment Type, 2023 to 2033
Figure 47: Europe Value (US$ Mn) by Distribution Channel, 2023 to 2033
Figure 48: Europe Value (US$ Mn) by Country, 2023 to 2033
Figure 49: Europe Value (US$ Mn) Analysis by Country, 2018 to 2033
Figure 50: Europe Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 51: Europe Y to o to Y Growth (%) Projections by Country, 2023 to 2033
Figure 52: Europe Value (US$ Mn) Analysis by Treatment Type, 2018 to 2033
Figure 53: Europe Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033
Figure 54: Europe Y to o to Y Growth (%) Projections by Treatment Type, 2023 to 2033
Figure 55: Europe Value (US$ Mn) Analysis by Distribution Channel, 2018 to 2033
Figure 56: Europe Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 57: Europe Y to o to Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 58: Europe Attractiveness by Treatment Type, 2023 to 2033
Figure 59: Europe Attractiveness by Distribution Channel, 2023 to 2033
Figure 60: Europe Attractiveness by Country, 2023 to 2033
Figure 61: Asia Pacific Value (US$ Mn) by Treatment Type, 2023 to 2033
Figure 62: Asia Pacific Value (US$ Mn) by Distribution Channel, 2023 to 2033
Figure 63: Asia Pacific Value (US$ Mn) by Country, 2023 to 2033
Figure 64: Asia Pacific Value (US$ Mn) Analysis by Country, 2018 to 2033
Figure 65: Asia Pacific Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 66: Asia Pacific Y o to Y Growth (%) Projections by Country, 2023 to 2033
Figure 67: Asia Pacific Value (US$ Mn) Analysis by Treatment Type, 2018 to 2033
Figure 68: Asia Pacific Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033
Figure 69: Asia Pacific Y o to Y Growth (%) Projections by Treatment Type, 2023 to 2033
Figure 70: Asia Pacific Value (US$ Mn) Analysis by Distribution Channel, 2018 to 2033
Figure 71: Asia Pacific Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 72: Asia Pacific Y to o to Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 73: Asia Pacific Attractiveness by Treatment Type, 2023 to 2033
Figure 74: Asia Pacific Attractiveness by Distribution Channel, 2023 to 2033
Figure 75: Asia Pacific Attractiveness by Country, 2023 to 2033
Figure 76: MEA Value (US$ Mn) by Treatment Type, 2023 to 2033
Figure 77: MEA Value (US$ Mn) by Distribution Channel, 2023 to 2033
Figure 78: MEA Value (US$ Mn) by Country, 2023 to 2033
Figure 79: MEA Value (US$ Mn) Analysis by Country, 2018 to 2033
Figure 80: MEA Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 81: MEA Y o to Y Growth (%) Projections by Country, 2023 to 2033
Figure 82: MEA Value (US$ Mn) Analysis by Treatment Type, 2018 to 2033
Figure 83: MEA Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033
Figure 84: MEA Y to o to Y Growth (%) Projections by Treatment Type, 2023 to 2033
Figure 85: MEA Value (US$ Mn) Analysis by Distribution Channel, 2018 to 2033
Figure 86: MEA Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 87: MEA Y o to Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 88: MEA Attractiveness by Treatment Type, 2023 to 2033
Figure 89: MEA Attractiveness by Distribution Channel, 2023 to 2033
Figure 90: MEA Attractiveness by Country, 2023 to 2033
The global arthrogryposis management market is valued at USD 250 million in 2023.
Stryker, Zimmer Biomet, DePuy Synthes, and Arthrex are key market players.
Surgical interventions are likely to remain preferred through 2033.
Players opt for product launches and strategic partnerships.
India, Japan, and China dominate the Asian market.
Explore Similar Insights
Arthrogryposis Management Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
